CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

TECARTUS

TECARTUSNeutral
AI Analysis

Summary

TECARTUS is indicated for treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia and relapsed/refractory mantle cell lymphoma. This appears to be a routine product information listing.

Importance:1/10
Sentiment:
0.00
CAR-Thematologic malignancyB-ALLmantle cell lymphoma

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on July 1, 2026 8:50 PM

Read Original